PE20071328A1 - Compuestos de heteroarilo biciclico que contienen nitrogeno y metodos de uso - Google Patents

Compuestos de heteroarilo biciclico que contienen nitrogeno y metodos de uso

Info

Publication number
PE20071328A1
PE20071328A1 PE2006001704A PE2006001704A PE20071328A1 PE 20071328 A1 PE20071328 A1 PE 20071328A1 PE 2006001704 A PE2006001704 A PE 2006001704A PE 2006001704 A PE2006001704 A PE 2006001704A PE 20071328 A1 PE20071328 A1 PE 20071328A1
Authority
PE
Peru
Prior art keywords
haloalkyl
halo
nitrogen
methods
heteroaryl compounds
Prior art date
Application number
PE2006001704A
Other languages
English (en)
Inventor
Morin Frenel F De
Jian J Chen
Elizabeth M Doherty
Stephen Hitchcock
Qi Huang
Joseph L Kim
Gang Liu
Thomas Nixey
Nick A Paras
Jeffrey Petkus
Daniel Martin Retz
Adrian Leonard Smith
Andrew Tasker
Jiawang Zhu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20071328A1 publication Critical patent/PE20071328A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE Z ES A, B, ENTRE OTROS; Z' ES UN ANILLO AROMATICO DE 5-6 MIEMBROS QUE OPCIONALMENTE COMPRENDEN 1-3 HETEROATOMOS SELECCIONADOS DE N, O Y S; R1 ES 1,2, ENTRE OTROS; A1,A1a,A2,A3 Y A4 SON CADA UNO CR6, N; X ES CR6R6, CO, NR6, ENTRE OTROS; R5 ES H, HALO, HALOALQUILO, NO2, CN, ENTRE OTROS; R6 ES H, HALO, HALOALQUILO, NO2, ENTRE OTROS; R2 ES HALO, HALOALQUILO, NO2, CN, ENTRE OTROS; R3 ES NH2, OH, SH, ENTRE OTROS; R17 ES H, HALO, HALOALQUILO, CN, OH, NH2, ACETILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 6-METIL-N5-(3-(4-PIRIMIDINIL)-2-PIRIDINI)N1-(3-(TRIFLUOROMETIL)FENIL)-1,5-ISOQUINOLINEDIAMINA; N1-(3-(DIETILAMIN)FENIL-6-METIL-N5-(3-(4-PIRIMIDINIL)-1,5-ISOQUINOLINEDIAMINA; ENTRE OTROS. DICHOS COMPUESTOS SON MODULADORES DE QUINASA RAF UTILES EN EL TRATAMIENTO DE MELANOMAS, TUMORES Y OTRAS CONDICIONES RELACIONADAS CON EL CANCER
PE2006001704A 2005-12-23 2006-12-26 Compuestos de heteroarilo biciclico que contienen nitrogeno y metodos de uso PE20071328A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75370505P 2005-12-23 2005-12-23
US11/643,261 US7989461B2 (en) 2005-12-23 2006-12-20 Substituted quinazolinamine compounds for the treatment of cancer

Publications (1)

Publication Number Publication Date
PE20071328A1 true PE20071328A1 (es) 2008-02-09

Family

ID=38016465

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001704A PE20071328A1 (es) 2005-12-23 2006-12-26 Compuestos de heteroarilo biciclico que contienen nitrogeno y metodos de uso

Country Status (9)

Country Link
US (2) US7989461B2 (es)
EP (2) EP1976836B9 (es)
AR (1) AR057997A1 (es)
AU (1) AU2006330888B2 (es)
CA (2) CA2634769C (es)
ES (1) ES2392673T3 (es)
PE (1) PE20071328A1 (es)
TW (1) TW200732339A (es)
WO (1) WO2007076092A2 (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06012613A (es) * 2004-05-07 2007-01-31 Amgen Inc Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
DE102005038947A1 (de) * 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
CA2612788A1 (en) 2005-06-24 2006-12-28 Steven Cesar Alfons De Jonghe Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
US7868177B2 (en) * 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
US8338435B2 (en) 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
WO2008089307A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
WO2008153947A2 (en) * 2007-06-07 2008-12-18 Amgen Inc. Heterocyclic compounds as raf kinase modulators
UY31137A1 (es) * 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
EP2649997B1 (en) * 2007-12-10 2019-01-23 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
BRPI0821227A2 (pt) 2007-12-19 2015-06-16 Cancer Rec Tech Ltd Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
DK2268623T3 (en) 2008-03-17 2015-06-29 Ambit Biosciences Corp QUINAZOLINE DERIVATIVES AS RAF CHINESE MODULATORS AND PROCEDURES FOR USE THEREOF
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2307400B1 (en) 2008-05-30 2014-04-23 Amgen, Inc Inhibitors of pi3 kinase
US8536187B2 (en) 2008-07-03 2013-09-17 Gilead Sciences, Inc. 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections
WO2010026122A1 (en) * 2008-09-02 2010-03-11 Novartis Ag Heterocyclic pim-kinase inhibitors
WO2010035745A1 (ja) 2008-09-25 2010-04-01 杏林製薬株式会社 ヘテロ環ビアリール誘導体及びそれらを有効成分とするｐｄｅ阻害剤
US20110224250A1 (en) * 2008-10-09 2011-09-15 Yasushi Kohno Isoquinoline derivative, and pde inhibitor comprising same as active ingredient
US8674095B2 (en) 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions
CA2755285C (en) 2009-03-20 2014-02-11 Yunxin Y. Bo Inhibitors of pi3 kinase
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
NZ597050A (en) 2009-06-29 2014-02-28 Incyte Corp Pyrimidinones as pi3k inhibitors
AU2010303218A1 (en) 2009-10-09 2012-05-10 Afraxis Holdings, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8H)-ones for the treatment of CNS disorders
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
AU2011209586B2 (en) 2010-02-01 2016-01-21 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro- 4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo [4,5-b]pyridin-7-yloxy)-phenyl] -urea and related compounds and their use in therapy
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
AR084366A1 (es) 2010-12-20 2013-05-08 Incyte Corp N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
EP2702042A1 (en) * 2011-04-28 2014-03-05 Bristol-Myers Squibb Company Novel bicyclic nitrogen containing heteroaryl tgr5 receptor modulators
CN102850337B (zh) * 2011-06-30 2015-01-07 四川大学 多氮唑联螺烯酮类化合物及其制备方法和用途
WO2013013614A1 (zh) * 2011-07-28 2013-01-31 南京英派药业有限公司 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
BR122019020716B1 (pt) 2011-09-02 2021-02-17 Incyte Holdings Corporation heterociclilaminas como inibidores de pi3k e composição farmacêutica que as compreende
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
AR089284A1 (es) 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
PT2797927T (pt) 2011-12-30 2019-10-30 Hanmi Pharm Ind Co Ltd Derivados de tieno[3,2-d]pirimidina com atividade inibidora de proteínas-cinases
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
JP6013029B2 (ja) * 2012-05-25 2016-10-25 千葉県 抗癌剤
CN106188045B (zh) * 2012-06-15 2018-01-16 广州源生医药科技有限公司 作为wnt信号传导抑制剂的化合物、组合物及其应用
WO2014052566A1 (en) * 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
RU2660429C2 (ru) * 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
TW201534597A (zh) * 2013-06-20 2015-09-16 Ab Science 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US10703746B2 (en) 2014-12-22 2020-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mutant IDH1 inhibitors useful for treating cancer
EP3237414B1 (en) 2014-12-24 2019-05-08 Gilead Sciences, Inc. Fused pyrimidine compounds for the tratment of hiv
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
KR101960624B1 (ko) 2014-12-24 2019-03-20 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 이소퀴놀린 화합물
MD3262046T2 (ro) 2015-02-27 2021-03-31 Incyte Corp Săruri de inhibitori ai PI3K și procedee pentru prepararea lor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2017207340A1 (de) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
US10294222B2 (en) * 2016-09-01 2019-05-21 Vanderbilt University Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2018060174A1 (de) 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
WO2018060072A1 (de) 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2018102455A1 (en) 2016-12-01 2018-06-07 Ignyta, Inc. Methods for the treatment of cancer
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
KR102328351B1 (ko) 2017-07-29 2021-11-19 루트리스 파마 엘티디. 신규한 BRaf 억제제 및 피부 반응의 치료를 위한 이의 용도
US10639313B2 (en) 2017-09-01 2020-05-05 Ndsu Research Foundation Compound for inhibition of delta-5-desaturase (D5D) and treatment of cancer and inflammation
WO2019070742A1 (en) * 2017-10-03 2019-04-11 Sidecar Therapeutics, Inc. APOPTOSIS SIGNAL REGULATION KINASE 1 (ASK 1) INHIBITORS COMPOUNDS
JP7416716B2 (ja) 2017-12-28 2024-01-17 トラクト ファーマシューティカルズ インコーポレイテッド 円柱上皮幹細胞のための幹細胞培養系およびそれに関連した使用法
CA3104808A1 (en) * 2018-07-02 2020-01-09 Ecole Polytechnique Federale De Lausanne (Epfl) Lactate enhancing compounds and uses thereof
RS64618B1 (sr) 2019-02-12 2023-10-31 Lutris Pharma Ltd Upotreba lokalnih kompozicija braf inhibitorа za lečenje radijacijskog dermatitisa
CN110343070B (zh) * 2019-08-14 2021-03-26 山东大学 一种微管蛋白抑制剂及其制备方法与应用
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
AU2021300429A1 (en) 2020-07-02 2023-02-16 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202302589A (zh) 2021-02-25 2023-01-16 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之螺環內醯胺
CN115322176B (zh) * 2021-10-27 2024-04-16 温州医科大学 一种2,3-二氢苯并呋喃基取代的1h-吲唑类化合物及其制备和应用
WO2023078252A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof
CN114516870B (zh) * 2022-02-10 2023-04-11 五邑大学 一种三唑并六元氮杂环-3-胺类化合物及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618670A (en) 1988-08-26 1997-04-08 The United States Of America As Represented By The Department Of Health & Human Services Detection method for c-raf-1 genes
US5156841A (en) 1988-08-26 1992-10-20 United States Of America Anti-tumor vaccine
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
DE19754774C2 (de) 1997-11-28 1999-11-25 Ulf R Rapp Transgenes nicht-menschliches Säugetier mit einer onkogenen Mutante des Raf-1-Gens
JP4437270B2 (ja) 1997-12-22 2010-03-24 バイエル コーポレイション 置換複素環式尿素を用いたｒａｆキナーゼの阻害
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
ES2228629T3 (es) 1999-11-22 2005-04-16 Smithkline Beecham Plc Derivados de imidazol y su uso como inhibidores de raf-quinasa.
WO2003016248A2 (en) 2001-08-17 2003-02-27 Bristol-Myers Squibb Company Patent Department Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
JP2005526008A (ja) 2001-12-04 2005-09-02 オニックス ファーマシューティカルズ，インコーポレイティド 癌を処置するためのｒａｆ−ｍｅｋ−ｅｒｋ経路インヒビター
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
WO2004063190A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Fused heterocyclic derivates as ppar modulators
MXPA05011536A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Acidos carboxilicos substituidos con fenilo como inhibidores de la proteina tirosina fosfatasa-1b.
US7335658B2 (en) * 2003-07-30 2008-02-26 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7390820B2 (en) 2003-08-25 2008-06-24 Amgen Inc. Substituted quinolinone derivatives and methods of use
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
CA2536954C (en) 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
CA2542329A1 (en) 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
ATE369862T1 (de) 2003-10-17 2007-09-15 4 Aza Ip Nv Heterocyclus-substituierte pteridin-derivate und ihre verwendung in der therapie
GB0326963D0 (en) 2003-11-19 2003-12-24 Glaxo Group Ltd Compounds
MXPA06012613A (es) * 2004-05-07 2007-01-31 Amgen Inc Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer

Also Published As

Publication number Publication date
US20070185324A1 (en) 2007-08-09
EP1976836B9 (en) 2013-02-06
CA2753405A1 (en) 2007-07-05
WO2007076092A3 (en) 2007-11-15
AU2006330888A1 (en) 2007-07-05
EP1976836A2 (en) 2008-10-08
US7989461B2 (en) 2011-08-02
WO2007076092A2 (en) 2007-07-05
AR057997A1 (es) 2008-01-09
CA2634769A1 (en) 2007-07-05
EP1976836B1 (en) 2012-08-22
AU2006330888B2 (en) 2011-07-28
TW200732339A (en) 2007-09-01
US20110251199A1 (en) 2011-10-13
ES2392673T3 (es) 2012-12-12
US8440674B2 (en) 2013-05-14
EP2481729A1 (en) 2012-08-01
CA2753405C (en) 2014-02-04
CA2634769C (en) 2011-12-13

Similar Documents

Publication Publication Date Title
PE20071328A1 (es) Compuestos de heteroarilo biciclico que contienen nitrogeno y metodos de uso
NO20070323L (no) Organiske forbindelser
ATE453639T1 (de) Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer
ATE398125T1 (de) Chinazolin-derivate als tgf-beta-inhibitoren
NO20061317L (no) Imidazopyridinderivater som induserbare NO-syntaseinhibatorer
TW200724539A (en) Benzimidazole derivative and use thereof
GT200400146A (es) Derivados sustituidos del dioxido de tiazol-benzoisotiazol, procedimiento para su preparacion y su uso
CY1110145T1 (el) Αλκυλο-υποκατεστημενες ινδολοκινοξαλινες
ATE509933T1 (de) Pentacyclische kinaseinhibitoren
NO20061344L (no) Imidazopyridinderivater som induserbare NO-syntaseoinhibitorer
IN2014DN02217A (es)
ATE403655T1 (de) Imidazopyridinderivate als induzierbare no- synthaseinhibitoren
TW200630095A (en) Pharmaceutical compounds
ATE398617T1 (de) Imidazoä4,5-büpyridinderivate als inhibitoren der induzierbaren no-synthase
AR034313A1 (es) Utilizacion de derivados de piridoindolona para la preparacion de medicamentos
TW200615274A (en) Chemical compounds
TH87496B (th) สารประกอบใหม่
TH87496A (th) สารประกอบใหม่
TH77896B (th) สารประกอบชนิดใหม่
ATE482951T1 (de) Benzimidazolderivat und anwendung davon
AR035699A1 (es) Asociacion de al menos un derivado de piridoindolona, composicion farmaceutica que comprende al menos un derivado de piridoindolona y kit para el tratamiento de la proliferacion de celulas tumorales
TH87428B (th) สารประกอบชนิดใหม่
TH88755A (th) สารประกอบทางเคมี
TH75725A (th) สารประกอบอิมิดาโซพิริดีน
TH106304B (th) อนุพันธ์ (เอธิลแอมีน) เอธิลโพรพาแนมีดเป็นเบตา 2 แอโกนิสท์ชนิดออกฤทธิ์นาน

Legal Events

Date Code Title Description
FD Application declared void or lapsed